Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by tdon1229on Jan 25, 2018 2:44pm
104 Views
Post# 27434362

RE:Clinical Trial Inclusion Exclusion Criteria

RE:Clinical Trial Inclusion Exclusion CriteriaYou have to read Exclusion 8 more carefully to understand that the first few patients were within the criteria set for this clinical trial.  NMIBC in the upper tract is allowed; i.e., any of the  T0, Ta, or Tis stages in the upper tract was not cause for exclusion.  That means that papillary carcinoma (as in Ta) and flat carcinoma (as in Tis) were not cause for exclusion.  Specifically, Exclusion 8 excludes "extravesical disease" which would be carcinoma that has begun to invade the muscle layer (MIBC).  The inner layer of tissue (mucosa) is the same in the ureters and the catch basin in the kidneys as it is in the inner wall of the bladder, and the cancer staging throughout is the same.  The supposition in the Nov. 8 NR was that seeding from the untreated regions above the treated bladder itself resulted in recurrence in the bladder, but the NMIBC in the treated bladder showed no progression, a result consistent with the supposition.  Your belief that the patients didn't meet the trail criteria appears to be in error. 
Bullboard Posts